- Two methods for the preparation of sitagliptin phosphate: Via chemical resolution and asymmetric hydrogenation
-
Two effective processes have been developed for the preparation of sitagliptin phosphate. The approach of chemical resolution obtained R-sitagliptin in five steps from commercially available starting materials using the inexpensive NaBH4 to reduce the enamine and then using (-)-di-p-toluoyl-l-tartaric acid to resolve racemates in 11% yield overall. The route successfully avoids the use of expensive noble metal as catalysts compared with traditional synthesis methods, resulting in greatly reduced costs and simplified synthetic routes. Other alternative asymmetric hydrogenation of β-ketomide routes for the synthesis of sitagliptin were found, two of the intermediates were synthesized for the first time. This journal is
- Ye, Fei,Zhang, Zhifeng,Zhao, Wenxia,Ding, Jianhai,Wang, Yali,Dang, Xueyan
-
p. 4805 - 4809
(2021/02/03)
-
- NOVEL PROCESS FOR THE PREPARATION OF DIPEPTIDYL PEPTIDASE-4 (DPP-4) ENZYME INHIBITOR
-
The present invention relates to a novel and improved process for the preparation of Sitagliptin of Formula (I) and its pharmaceutically acceptable salts. The present invention also relates to novel intermediates and process for the preparation of intermediates used in the preparation of Sitagliptin.
- -
-
Page/Page column 16
(2016/08/10)
-
- A process for the conversion of isomer
-
The invention relates to a method for recycling an isomer such as sitagliptin and belongs to the technical field of pharmacy. The isomer and mercaptan are transformed into a racemate under the action of a free radical initiator, and then a compound needin
- -
-
Paragraph 0053; 0054
(2016/11/17)
-
- PROCESSES FOR PREPARING 4-OXO-4-[3-(TRIFLUOROMETHYL)-5,6- DIHYDRO [L,2,41-TRIAZOLO[43-A]PYRAZIN-7(8H)-YL]-L-(2,4,5- TRIFLUOROPHENYL)BUTAN-2-AMINE
-
The present invention relates to synthesis of 4-oxo-4-[3-(trifluoromethyl)-5,6- dihydro [l,2,4]-triazolo[4,3-a]pyrazin-7(8H)-yl]-l-(2,4,5-trifluorophenyl)butan-2- amine of Formula (I) either in its racemic (R/S) form or any of its optically active (S) or (R) forms or enantiomeric excess mixture of any of the forms by novel processes. The invention further relates to certain novel intermediates useful in the preparation of compound of Formula (I) and processes for their preparation.
- -
-
-
- PROCESS FOR PREPARATION OF (2R)-4-OXO-4-[3- (TRIFLUOROMETHYL)-5,6-DIHYDRO [1,2,4]-TRIAZOLO[4,3-A]PYRAZIN- 7(8H)-YL]-L-(2,4,5-TRIFLUOROPHENYL)BUTAN-2-AMINE and NEW IMPURITIES IN PREPARATION THEREOF
-
The present invention relates to synthesis of β-amino acid derivatives of formula (I) and its salts of formula (Ia) by a novel process. The process comprises the reduction of a protected or unprotected prochiral β-amino acrylic acid or derivative there of, by using borane containing reducing agents at atmospheric pressure. The resulting racemic β-amino compound is resolved to a pure stereoisomer of formula (I), specifically to (2R)-4-oxo-4-[3-Ctrifluoromethyl)-5,6-dihydrol[1,2,4]triazolo[4,3-alpyrazin-7(8H)-yl]-1-(2,4,4-trifluorophenyl)butan-2-amine. In an embodiment the invention disclosed polymorphic forms of formula (I), phosphate salt of formula (I) and also a Dibenzoyl-L-tartaric acid salt of formula (I).
- -
-
Page/Page column 24
(2011/09/20)
-
- A NOVEL SYNTHETIC APPROACH TO ?-AMINOBUTYRYL SUBSTITUTED COMPOUNDS
-
The present invention relates to process to prepare β-aminobutyryl compounds of formula (I), wherein Q is N, CH, C-CF3 or C-phenyl, preferably N, and R10 is H, C1-C4-alkyl or fluorinated C1C2-alkyl, preferably trifluoromethyl, and wherein X is halogen selected from fluoro, chloro, or bromo, preferably fluoro, same or different, and n is 1-4.
- -
-
-
- A novel synthetic approach to ?-aminobutyryl substituted compounds
-
The present invention relates to process to prepare β-aminobutyryl compounds of formula (I) wherein Q is N, CH, C-CF3 or C-phenyl, preferably N, and R10 is H, C1-C4-alkyl or fluorinated C1-C2-alkyl, preferably trifluoromethyl, and wherein X is halogen selected from fluoro, chloro, or bromo, preferably fluoro, same or different, and n is 1-4.
- -
-
-
- PROCESS FOR THE PREPARATION OF SITAGLIPTIN AND ITS INTERMEDIATES
-
The present invention relates to novel and improved processes for the preparation of Sitagliptin compound of formula (1) and its intermediates.
- -
-
Page/Page column 67
(2010/11/05)
-
- IMPROVED PROCESS FOR PREPARATION OF (2R)-4-OXO-4-[3- (TRIFLUOROMETHYL)-5,6-DIHYDRO [1,2,4]-TRIAZOLO[4,3-A]PYRAZIN- 7(8H)-YL]-L-(2,4,5-TRIFLUOROPHENYL)BUTAN-2-AMINE and NEW IMPURITIES IN PREPARATION THEREOF
-
The present invention relates to synthesis of β-amino acid derivatives of formula (I) and its salts of formula (Ia) by a novel process. The process comprises the reduction of a protected or unprotected prochiral β-amino acrylic acid or derivative there of, by using borane containing reducing agents at atmospheric pressure. The resulting racemic β-amino compound is resolved to a pure stereoisomer of formula (I), specifically to (2R)-4-oxo-4- [3-Ctrifluoromethyl)-5, 6-dihydrol [1,2,4]triazolo [4,3-alpyrazin-7(8H)-yl]-1-(2,4,4-trifluorophenyl)butan-2-amine. In an embodiment the invention disclosed polymorphic forms of formula (I), phosphate salt of formula (I) and also a Dibenzoyl-L-tartaric acid salt of formula (I).
- -
-
Page/Page column 60
(2010/04/25)
-
- PROCESS FOR THE PREPARATION OF R-SITAGLIPTIN AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF
-
The present invention provides processes for the preparation of R-sitagliptin and its pharmaceutically acceptable salts thereof.
- -
-
Page/Page column 11
(2010/12/29)
-
- PROCESSES FOR THE PREPARATION OF SITAGLIPTIN AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF
-
There is provided salts and polymorphs of sitagliptin, processes for the preparation thereof, and pharmaceutical compositions comprising the same.
- -
-
Page/Page column 28
(2009/08/14)
-
- A PROCESS FOR THE PREPARATION OF R-SIT AGLIPTIN AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF
-
The present invention provides processes for the preparation of R-sitagliptin and its pharmaceutically acceptable salts thereof.
- -
-
Page/Page column 24-25; 28
(2009/08/14)
-